Adherence to Nucleoside/Nucleotide Analogue Treatment in Patients with Chronic Hepatitis B

Abstract

Background: Adherence to medication is an important aspect of preventing drug resistance and treatment failure in patients receiving nucleos(t)ide analogues for chronic hepatitis B. Aims: To assess adherence to nucleoside/nucleotide analogues in chronic hepatitis B treatment and to determine factors associated with non-adherence. Study Design: Cross-sectional study. Methods: The study enrolled 85 chronic hepatitis B patients who had been receiving nucleoside/nucleotide analogues for ≥3 months. A questionnaire was completed by patients themselves, and adherence was evaluated based on patients’ self-reporting. The use of at least 95% of the drugs in the previous month was considered as adequate adherence. Results: Adherence was adequate in 82.4% of patients. Female gender (p=0.003), unemployment (p=0.041) and lower monthly family income (p=0.001) were related to lower adherence. Better adherence was significantly linked to adequate basic knowledge regarding chronic hepatitis B (p=0.049), longer treatment duration than 12 months (p<0.001), previous use of other medications for chronic hepatitis B (p=0.014) and regular follow-up by the same physician (p<0.001). Conclusion: Counselling patients about their disease state and the consequences of non-adherence is an important intervention for enhancing adherence. Naïve patients should be followed up more frequently to reinforce adherence.

Keywords

• Medication adherence, chronic hepatitis B, treatment outcome, nucleoside/nucleotide analogues

References

1. 1. Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology 2016;63:261-83.
2. 2. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of Chronic Hepatitis B infection. J of Hepatol 2012;57:167-185.
3. 3. Ha NB, Ha NB, Garcia RT, Trinh HN, Chaung KT, Nguyen HA, et al. Medication nonadherence with long-term management of patients with hepatitis B e antigen-negative chronic hepatitis B. Dig Dis Sci 2011;56:2423-31.
4. 4. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487-97.
5. 5. Sabate E. Adherence to long-term therapies. Evidence for action. Geneva: World Health Organization 2003. Available from URL: http://www.who. int/chp/knowledge/publications/adherence_full_report.pdf
6. 6. Chotiyaputta W, Peterson C, Ditah FA, Goodwin D, Lok AS. Persistance and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B. J Hepatol 2011;54:12-8.
7. 7. Lee M, Keeffe EB. Study of adherence comes to the treatment of chronic hepatitis B. J Hepatol 2011;54:6-8.
8. 8. Haynes RB, McDonald HP, Garg AX. Helping patients follow prescribed treatment: clinical applications. JAMA 2002;288:2880-3.

9. 9. Sethi AK, Celentano DD, Gange SJ, Moore RD, Gallant JE. Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis 2003;37:1112-8.
10. 10. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:21-30.
11. 11. Mills EJ, Nachega JB, Buchan I, Orbinski J, Attaran A, Singh S, et al. Adherence to antiretroviral therapy in Sub-Saharan Africa and North America. JAMA 2006;296:679-90.
12. 12. Jin J, Sklar GE, Min Sen Oh V, Chuen Li S. Factors affecting therapeutic compliance: A review from the patient’s perspective. Ther Clin Risk Manag 2008;4:269-86.
13. 13. Fumaz CR, Munoz-Moreno JA, Molto J, Ferrer MJ, Lopez-Blazquez R, Negredo E, et al. Sustained antiretroviral treatment adherence in survivors of the pre-HAART era: attitudes and beliefs. AIDS Care 2008;20:796-805.
14. 14. Puskas CM, Forrest JI, Parashar S, Salters KA, Cescon AM, Kaida A, et al. Women and vulnerability to HAART non-adherence: a literature review of treatment adherence by gender from 2000 to 2011. Curr HIV/AIDS Rep 2011;8:277-87.
15. 15. Adler NE, Newman K. Socioeconomic disparities in health: Pathways and policies. Health Aff (Millwood) 2002;21:60-76.
16. 16. Falagas ME, Zarkadoulia EA, Pliatsika PA, Panos G. Socioeconomic status (SES) as a determinant of adherence to treatment in HIV infected patients: a systematic review of the literature. Retrovirology 2008;5:13.
17. 17. Cauldbeck MB, O’Connor C, O’Conner MB, Saunders JA, Rao B, Mallesh VG, et al. Adherence to anti-retroviral therapy among HIV patients in Bangalore, India. AIDS Res Ther 2009;6:7.
18. 18. Martin LR, Williams SL, Haskard KB, DiMatteo MR. The challenge of patient adherence. Ther Clin Risk Manag 2005;1:189-99.
19. 19. Zolnierek KB, DiMatteo MR. Physician communication and patient adherence to treatment: a meta-analysis. Med Care 2009;47:826-34.
20. 20. Cacoub P, Ouzan D, Melin P, Lang JP, Rotily M, Fontanges T, et al. Patient education improves adherence to peg-interferon and ribavirin in chronic genotype 2 or 3 hepatitis C virus infection: a prospective, real-life, observational study. World J Gastroenterol 2008;14:6195-203.
21. 21. Piette JD, Schillinger D, Potter MB, Heisler M. Dimensions of patientprovider communication and diabetes self-care in an ethnically diverse population. J Gen Intern Med 2003;18:624-33.
22. 22. Barber N, Parsons J, Clifford S, Darracott R, Horne R. Patients’ problems with new medication for chronic conditions. Qual Saf Health Care 2004;13:172-5.
23. 23. DiMatteo MR, Haskard KB, Williams SL. Health beliefs, disease severity and patient adherence: a meta-analysis. Med Care 2007;45:521-8.
24. 24. Gish RG, Lok AS, Chang TT, de Man RA, Gadano A, Sollano J, et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007;133:1437-44.
25. 25. Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008;359:2442-55.